Patients in the daratumumab group received intravenous daratumumab at a dose of 16 mg per kilogram of body weight once weekly during cycles 1 and 2, every 2 weeks during cycles 3 through 6 ...

12 On the basis of these findings, daratumumab monotherapy at a dose of 16 mg per kilogram of body weight was approved by the Food and Drug Administration for the treatment of multiple myeloma in ...

A retrospective chart review at the Mayo Clinic reviewed eligible patients with multiple myeloma or amyloid light-chain (AL) amyloidosis who received their first dose of daratumumab within the 4 ...

Daratumumab (Darzalex, Janssen) in combination with lenalidomide and dexamethasone is indicated for 'the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ...

Niewinski and colleagues aimed to assess real-world use of daratumumab for patients with multiple myeloma and renal insufficiency. They performed a retrospective chart review of 101 patients ...

The benefit of daratumumab was generally consistent across the study's prespecified subgroups, and the relative dose intensity of VRd was not affected by combination with daratumumab. In terms of ...

Evaluated doses — based on the approved weekly 16-mg/kg IV dose for daratumumab — were 1,200 mg (n = 8; median age, 65.5 years) or 1,800 mg (n = 45; median age, 63 years). Treatment was ...

2.1 Daratumumab (Darzalex, Janssen) is indicated 'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior ...